Preview

Медицинский Совет

Расширенный поиск

ЛЕЧЕНИЕ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ С СОХРАНЕННОЙ ФРАКЦИЕЙ ВЫБРОСА ЛЕВОГО ЖЕЛУДОЧКА У ПАЦИЕНТОВ С ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ: ПОТЕНЦИАЛЬНАЯ РОЛЬ СТАТИНОВ

https://doi.org/10.21518/2079-701X-2017-20-26-31

Полный текст:

Аннотация

В проспективном рандомизированном исследовании участвовали 167 больных с хронической сердечной недостаточностью (ХСН) II/III функционального класса и сохраненной фракцией выброса левого желудочка (ФВ ЛЖ) на фоне гипертонической болезни III стадии. В дополнение к антигипертензивной терапии периндоприлом и верапамилом SR (n = 85) или амлодипином (n = 82) назначался аторвастатин, который регулярно принимали 50,6 и 48,8% пациентов соответственно. Через 12 мес. при каждом варианте лечения происходило улучшение клинического состояния и качества жизни больных, увеличивалось расстояние, пройденное в тесте с 6-минутной ходьбой. У пациентов, получавших аторвастатин, существенно снижался уровень N-концевого предшественника мозгового натрийуретического пептида, отмечалась тенденция к улучшению показателей диастолической функции ЛЖ. Добавление аторвастатина к лечению ХСН с сохраненной ФВ ЛЖ целесообразно в связи с потенциальной возможностью улучшения прогноза больных.

Об авторах

С. Г. Канорский
Кубанский государственный медицинский университет Минздрава России.
Россия

доктор медицинских наук; профессор.

 Краснодар. 



А. Ф. Середа
Кубанский государственный медицинский университет Минздрава России.
Россия
Краснодар.


Список литературы

1. Messerli FH, Rimoldi SF, Bangalore S. The Transition From Hypertension to Heart Failure: Contemporary Update. JACC Heart Fail, 2017, 5(8): 543–551.

2. Yamamoto K. Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction. Yonago Acta Med, 2017, 60(2): 71–76.

3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol, 2017, 70(6): 776–803.

4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: he Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J, 2016, 37(27): 2129–2200.

5. Канорский С.Г., Середа А.Ф. Сравнение верапамила и амлодипина при лечении больных с хронической сердечной недостаточностью и сохраненной фракцией выброса левого желудочка. Кардиология, 2016, 56(12): 27–32.

6. Hung MJ, Cherng WJ, Kuo LT, Wang CH. Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int J Clin Pract, 2002, 56(1): 57–62.

7. Patel K, Fonarow GC, Ahmed M, Morgan C, Kilgore M, Love TE, et al. Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction. Circ Heart Fail, 2014, 7(6): 945–952.

8. Fukuta H, Goto T, Wakami K, Ohte N. The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses. Int J Cardiol, 2016, 214: 301–306.

9. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal let ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J, 2007, 28(20): 2539–2550.

10. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr, 2009, 22(2): 107–133.

11. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging, 2015, 16(3): 233–270.

12. Jhund PS, Anand IS, Komajda M, Claggett BL, McKelvie RS, Zile MR, et al. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. Eur J Heart Fail, 2015, 17(8): 809–817.

13. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 2016, 37(39): 2999–3058.

14. Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res, 2017, 120(1): 229–243.

15. Bedi O, Dhawan V, Sharma PL, Kumar P. Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol, 2016, 389(7): 695–712.

16. Kudo S, Satoh K, Nogi M, Suzuki K, Sunamura S, Omura J, et al. SmgGDS as a Crucial Mediator of the Inhibitory Effects of Statins on Cardiac Hypertrophy and Fibrosis: Novel Mechanism of the Pleiotropic Effects of Statins. Hypertension, 2016, 67(5): 878–889.

17. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med, 2007, 357(22): 2248–2261.

18. Cleland JG, McMurray JJ, Kjekshus J, Cornel JH, Dunselman P, Fonseca C, et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol, 2009, 54(20): 1850–1859.

19. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet, 2008, 372(9645): 1231–1239.

20. Bonsu KO, Reidpath DD, Kadirvelu A. Lipophilic Statin Versus Rosuvastatin (Hydrophilic) Treatment for Heart Failure: a Meta-Analysis and Adjusted Indirect Comparison of Randomised Trials. Cardiovasc Drugs Ther, 2016, 30(2): 177–188.

21. Takano H, Mizuma H, Kuwabara Y, Sato Y, Shindo S, Kotooka N, et al. Effects of pitavastatin in Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study). Circ J, 2013, 77(4): 917–925.

22. Kihara Y. Statin therapy in chronic heart failure: frog prince or bare frog? Circ J, 2013, 77(4): 895–897.

23. Silva S, Lourenço P, Paulo C, Ferreira E, Lebreiro A, Sousa A, et al. Statin-induced low cholesterol is not associated with poor outcome in chronic heart failure. J Cardiovasc Pharmacol Ther, 2012, 17(3): 284–290.

24. Shah R, Wang Y, Foody JM. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or = 65 years of age with heart failure and preserved left ventricular systolic function. Am J Cardiol, 2008, 101(2): 217–222.

25. Roik M, Starczewska MH, Huczek Z, Kocha now ski J, Opolski G. Statin therapy and mortality among patients hospitalized with heart failure and preserved left ventricular function–a preliminary report. Acta Cardiol, 2008, 63(6): 683–692.

26. Liu G, Zheng XX, Xu YL, Ru J, Hui RT, Huang XH. Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction. Am J Cardiol, 2014, 113(7): 1198–1204.

27. Alehagen U, Benson L, Edner M, Dahlström U, Lund LH. Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of ≥50. Circ Heart Fail, 2015, 8(5): 862–870.

28. Nochioka K, Sakata Y, Miyata S, Miura M, Takada T, Tadaki S, et al. Prognostic impact of statin use in patients with heart failure and preserved ejection fraction. Circ J, 2015, 79(3): 574–582.

29. Castro PF, Miranda R, Verdejo HE, Greig D, Gabrielli LA, Alcaino H, et al. Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity. J Heart Lung Transplant, 2008, 27(4): 435–441.

30. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, Rysz J, Maciejewski M, Banach M. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit, 2009, 15(12): MS12–MS23.

31. Kelly JP, Dunning A, Schulte PJ, Fiuzat M, Leifer ES, Fleg JL, et al. Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION. JACC Heart Fail, 2016, 4(8): 617–624.

32. Lee HY, Cho HJ, Kim HY, Jeon HK, Shin JH, Kang SM, et al. Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study. Korean J Intern Med, 2014, 29(6): 754–763.

33. Perez AC, Jhund P, Preiss D, Kjekshus J, McMurray JJ. Effect of rosuvastatin on fatigue in patients with heart failure. J Am Coll Cardiol, 2013, 61(10): 1121–1122.

34. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003, 361(9364): 1149–1158.

35. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, et al. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation, 2016, 134(1): 73–90.


Просмотров: 608


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)